Coagulation markers in diagnostic and monitoring of thromboembolic complication in COVID-19

Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2). Aim. The aim of this ar...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical and experimental medicine 2021, Vol.19 (3), p.241-245
Main Authors: Czarnecka-Czapczyńska, Magdalena, Bartusik-Aebisher, Dorota, Krupka-Olek, Magdalena, Aebisher, David, Cieślar, Grzegorz, Latos, Wojciech, Kawczyk-Krupka, Aleksandra
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2). Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19. Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19. Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts. Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.
ISSN:2544-2406
2544-1361
DOI:10.15584/ejcem.2021.3.5